Development of a Risk Assessment Tool for Incontinence-associated Dermatitis (IAD): a Cohort Study on the Predictive Performance of Risk Factors for IAD
Launched by ÖREBRO UNIVERSITY, SWEDEN · May 16, 2025
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Problem Statement:
Incontinence-Associated Dermatitis (IAD) is a type of irritant contact dermatitis caused by prolonged skin exposure to urine and/or feces. It commonly affects individuals with incontinence. IAD is associated with decreased quality of life, increased care burden, loss of independence, and higher susceptibility to secondary infections and pressure ulcers. These complications lead to prolonged hospital stays and increased healthcare costs.
Despite its clinical relevance, there is insufficient consensus regarding the most critical risk factors for IAD. Existing literature p...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient or their legally authorized representative signed informed consent.
- • The patient is aged 18 years or older.
- • The patient suffers from incontinence\* (urinary, faecal, double incontinence).
- • The patient is free of IAD at inclusion. \*Incontinence is defined as involuntary loss of urine and/or stool.
- Exclusion Criteria:
- • Patients admitted to emergency departments, paediatric units, maternity units, psychiatric units, and palliative care units.
- • Patients who are receiving end-of-life care.
About örebro University, Sweden
Örebro University, located in Sweden, is a prominent academic institution dedicated to advancing research and education in various fields, including health sciences. The university actively engages in clinical trials to enhance medical knowledge and improve patient outcomes. With a strong focus on interdisciplinary collaboration, Örebro University fosters innovative research initiatives that align with ethical standards and regulatory requirements. Its commitment to excellence in clinical research is supported by a team of experienced researchers and state-of-the-art facilities, making it a key player in the global medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Uppsala, , Sweden
Kortrijk, , Belgium
Ghent, , Belgium
Ghent, , Belgium
Izegem, , Belgium
Rumbeke, , Belgium
Veurne, , Belgium
Patients applied
Trial Officials
Dimitri Beeckman, Professor, PhD, MSc, RN
Principal Investigator
Swedish Centre for Skin and Wound Research (SCENTR), School of Health Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported